Alphatec (NASDAQ:ATEC) Reaches New 12-Month Low After Analyst Downgrade

Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC – Get Free Report) reached a new 52-week low during mid-day trading on Monday after Weiss Ratings downgraded the stock from a sell (d-) rating to a sell (e+) rating. The company traded as low as $6.78 and last traded at $6.8350, with a volume of 735,037 shares traded. The stock had previously closed at $7.07.

A number of other equities analysts have also commented on ATEC. JPMorgan Chase & Co. cut their price target on shares of Alphatec from $16.00 to $15.00 and set an “overweight” rating on the stock in a report on Friday, October 30th. Wall Street Zen cut Alphatec from a “buy” rating to a “hold” rating in a report on Sunday, October 11th. Stephens initiated coverage on Alphatec in a research report on Thursday, July 23rd. They set an “overweight” rating and a $15.00 target price on the stock. HC Wainwright dropped their price target on Alphatec from $24.00 to $20.00 and set a “buy” rating on the stock in a report on Friday. Finally, UBS Group lowered Alphatec from a “buy” rating to a “neutral” rating and lowered their target price for the company from $15.00 to $8.50 in a research note on Wednesday, November 4th. Eleven investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $15.37.

View Our Latest Analysis on Alphatec

Insider Transactions at Alphatec

In other news, CEO Patrick Miles acquired 115,000 shares of the stock in a transaction dated Thursday, September 10th. The stock was purchased at an average cost of $8.81 per share, with a total value of $1,013,150.00. Following the completion of the purchase, the chief executive officer owned 5,893,551 shares in the company, valued at approximately $51,922,184.31. The trade was a 1.99% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director David Demski bought 60,000 shares of the company’s stock in a transaction dated Friday, October 30th. The shares were purchased at an average price of $6.81 per share, with a total value of $408,600.00. Following the completion of the acquisition, the director owned 491,635 shares of the company’s stock, valued at $3,348,034.35. This trade represents a 13.90% increase in their position. The SEC filing for this purchase provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.48% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Alphatec

A number of large investors have recently made changes to their positions in the business. Marshall Wace LLP purchased a new stake in shares of Alphatec in the 3rd quarter worth about $24,355,000. First Trust Advisors LP increased its position in shares of Alphatec by 22.3% during the third quarter. First Trust Advisors LP now owns 239,325 shares of the medical technology company’s stock valued at $2,470,000 after buying an additional 43,633 shares during the period. Private Advisor Group LLC purchased a new position in shares of Alphatec during the third quarter valued at about $115,000. Ieq Capital LLC increased its position in shares of Alphatec by 47.6% during the third quarter. Ieq Capital LLC now owns 154,251 shares of the medical technology company’s stock valued at $1,592,000 after buying an additional 49,723 shares during the period. Finally, Focus Advisor Solutions LLC bought a new position in Alphatec in the third quarter worth about $152,000. 66.35% of the stock is currently owned by institutional investors.

Alphatec Price Performance

The stock’s 50 day moving average is $9.75 and its 200-day moving average is $10.17. The company has a market capitalization of $1.06 billion, a P/E ratio of -12.39 and a beta of 0.88.

Alphatec (NASDAQ:ATEC – Get Free Report) last posted its earnings results on Thursday, October 29th. The medical technology company reported $0.09 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.01). Alphatec had a negative return on equity of 6,752.24% and a negative net margin of 10.35%. The firm had revenue of $221.17 million for the quarter, compared to analysts’ expectations of $225.16 million. During the same quarter last year, the company posted $0.03 EPS. The firm’s revenue was up 12.6% on a year-over-year basis. On average, equities research analysts anticipate that Alphatec Holdings, Inc. will post -0.40 EPS for the current year.

Alphatec Company Profile

(Get Free Report)

Alphatec Holdings, Inc. is a medical technology company focused on developing and marketing products for spine surgery. Its offerings are intended to support the surgical treatment of spinal disorders and include implants, biologics, instruments and access systems, along with technologies designed to assist surgeons during procedures. The company’s product portfolio includes solutions for several surgical approaches and stages of spine care, including systems for planning, accessing and instrumenting the spine.

Featured Stories

Receive News & Ratings for Alphatec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alphatec and related companies with MarketBeat.com's FREE daily email newsletter.